|
Updated results from first-in-human phase 1 dose-escalation trial of TAK-102, a GPC3-targeted armored CAR T cells, in patients with advanced solid tumors. |
|
|
Honoraria - Bristol-Myers Squibb Japan; Chugai Pharma; Daiichi Sankyo/UCB Japan; Nobelpharma; Ono Pharmaceutical; PAREXEL INTERNATIONAL; Pfizer; Pfizer; Pfizer; Taiho Pharmaceutical |
Consulting or Advisory Role - Rebirthel (Inst); Thyas Co. Ltd (Inst) |
Research Funding - Abbvie (Inst); Chugai Pharma (Inst); KBBM (Inst); Lilly Japan (Inst); Novartis (Inst); Otsuka (Inst); Taiho Pharmaceutical (Inst); Taisho Pharmaceutical Holdings (Inst); Takeda (Inst); Zymeworks (Inst) |
|
|
Honoraria - Lilly Japan; Taiho Pharmaceutical; Takeda |
Consulting or Advisory Role - Abbvie; Amgen; Boehringer Ingelheim; Incyte; Janssen Oncology; Takeda |
Research Funding - Abbvie (Inst); Amgen (Inst); Astellas Pharma (Inst); AstraZeneca (Inst); Boehringer Ingelheim (Inst); Carna Biosciences (Inst); Chugai Pharma (Inst); Daiichi Sankyo/UCB Japan (Inst); Genmab (Inst); GlaxoSmithKline (Inst); Incyte (Inst); Janssen Oncology (Inst); Jiangsu Hengrui Pharmaceuticals (Inst); Lilly (Inst); Merck Serono (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst) |
Travel, Accommodations, Expenses - Amgen; Chugai Pharma; Incyte |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
Honoraria - Chugai Pharma; Eisai; Sanofi |
Speakers' Bureau - Chugai Pharma; Eisai |
Research Funding - Abbvie; AZD; Boehringer Ingelheim; Chugai Pharma; Eisai; Incyte; Lilly |
|
|
No Relationships to Disclose |
|
|
Honoraria - Abbvie; AstraZeneca; Bristol-Myers Squibb; Chugai Pharma; Eisai; Fujifilm; Guardant Health; Incyte; Lilly Japan; MSD; Nihonkayaku; Nobelpharma; Novartis; Ono Pharmaceutical; SERVIER; Taiho Pharmaceutical; Taisho Pharmaceutical Holdings; Takeda; Teijin Pharma; Yakult Pharmaceutical |
Consulting or Advisory Role - Astellas Pharma; AstraZeneca; Boehringer Ingelheim; Boston Scientific; Chugai Pharma; Eisai; Guardant Health; MSD; Novartis; Roche; SERVIER |
Research Funding - AstraZeneca (Inst); Bayer Yakuhin (Inst); Boehringer Ingelheim (Inst); Bristol-Myers Squibb (Inst); Chiome Bioscience (Inst); Chugai Pharma (Inst); Delta-Fly Pharma (Inst); Eisai (Inst); InVitae (Inst); J-Pharma (Inst); Lilly Japan (Inst); Merck (Inst); Merus NV (Inst); MSD (Inst); Nihon Servier (Inst); Nobelpharma (Inst); Novartis (Inst); Ono Pharmaceutical (Inst); Rakuten Medical Japan (Inst); Syneos Health (Inst) |
|
|
|
Research Funding - Nihon Servier (Inst) |
|
|
No Relationships to Disclose |
|
|
Employment - Takeda Pharmaceutical Company Limited Cure Bioscience |
|
|
|
Stock and Other Ownership Interests - Takeda |
|
|
|
Stock and Other Ownership Interests - Takeda |
Research Funding - Takeda |
Patents, Royalties, Other Intellectual Property - Takeda |
Travel, Accommodations, Expenses - Takeda |
|
|
|
Stock and Other Ownership Interests - Takeda |
|
|
Leadership - Noile-Immune Biotech Inc. |
Stock and Other Ownership Interests - Noile-Immune Biotech Inc. |
Honoraria - Abbvie; Bristol-Myers Squibb; Daiichi Sankyo; Eisai; Gilead Sciences K.K.; Kyowa Kirin; Merck; Merck Sharp & Dohme; Novartis; Ono Pharmaceutical; Takeda |
Consulting or Advisory Role - Astellas Pharma; Daiichi Sankyo; Kyowa Kirin; Ono Pharmaceutical |
Research Funding - Chugai Pharma; Noile-Immune Biotech Inc. |
|
|
Honoraria - Chugai Pharma; Sysmex |
Consulting or Advisory Role - Amgen |
Research Funding - Chugai Pharma (Inst); Daiichi Sankyo RD Novare (Inst); Lilly (Inst); Novartis (Inst); PACT Pharma (Inst); Pfizer (Inst); Takeda (Inst); Zymeworks (Inst) |